Holy Name was the first hospital in the nation to offer monoclonal antibody therapy through clinical trials to patients at
risk for severe complications from COVID-19.
Monoclonal antibody therapy actively disables the virus, preventing it from making patients seriously ill. The treatment is developed and
manufactured in a lab based on antibodies provided by people who have recovered from COVID; it is not a blood product. The treatment is
administered intravenously in the Medical Center’s COVID Infusion Center for those who are not hospitalized.
As the Omicron variant spreads, we have found that certain monoclonal antibody treatments are not effective for patients who become infected with
this variant. There is one monoclonal antibody treatment that is currently effective against the Omicron variant.